Brazilian firm plans to export Russian COVID vaccine to South America

Sputnik V vaccine: Indian doctor on scientific board

Russian Federation is seeking the European Union's (EU's) approval for its Sputnik V vaccine against the Coronavirus (COVID-19), the disease caused by the novel coronavirus, and has submitted an application to the relevant authority.

Russian Federation was the first country to register a coronavirus vaccine in August despite Sputnik V's incomplete clinical trials at the time, raising concerns over the fast-tracked procedure.

The Sputnik V vaccine has been approved in Argentina, Belarus, Serbia and several other countries.

In late December, Turkmenistan expressed its interest in procuring the Sputnik V vaccine from Russian Federation within the framework of its national plan for the purchase of Covid-19 vaccines and its delivery to the country.

AstraZeneca first announced plans to explore the possibility of working with Russian scientists on a combined vaccine in December, interpreted by Moscow as a vote of confidence in its vaccine.

According to the latest claim from Rospotrebnadzor, the consumer health watchdog of Russia, EpiVacCorona proved 100% effective in clinical trials.

Mexico, which is seeing a reduction in deliveries of Covid-19 vaccine doses from Pfizer Inc, has said it aimed to make up for the shortfall with doses from other providers. In addition, it demonstrated 100% efficacy against severe Covid-19 cases. We will see how much confidence the new vaccine produced will provide in the world public opinion in the coming days. However, it is not yet clear how many people participated in the phase studies of the vaccine.

Vasanthapuram Ravi, Dean (Basic Sciences) at National Institute of Mental Health and Neurosciences (NIMHANS), is part of the team of leading scientists in virology, microbiology, genetics and biotechnology from countries including Argentina, Croatia, France, Germany, Sweden, the United Kingdom and the U.S., a note from RDIF, Russia's sovereign wealth fund, said.

Related:

Comments


Other news